PRHSX: T. Rowe Price Health Sciences

Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

PRHSX T. Rowe Price Health Sciences

  • Fund
  • PRHSX
  • Price as of: Oct 18, 2019
  • $74.70 + $0.12 + 0.16%

PRHSX - Profile

Vitals

  • YTD Return 11.5%
  • 3 Yr Annualized Return 6.4%
  • 5 Yr Annualized Return 2.3%
  • Net Assets $11.9 B
  • Holdings in Top 10 37.8%

52 WEEK LOW AND HIGH

$74.70
$62.31
$81.17

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.77%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 43.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

STANDARD (TAXABLE)

$2,500

IRA

$1,000

Fund Classification

PRIMARY CATEGORY

  • Fund Type Open End Mutual Fund
  • Investment Style Health

Distributions

  • YTD Total Return 11.5%
  • 3 Yr Annualized Total Return 6.4%
  • 5 Yr Annualized Total Return 2.3%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio 0.05%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name T. Rowe Price Health Sciences Fund
  • Fund Family Name T. Rowe Price
  • Inception Date Dec 29, 1995
  • Shares Outstanding N/A
  • Share Class No Load
  • Currency USD
  • Domiciled Country United States
  • Manager Ziad Bakri

Fund Description

The T. Rowe Price Health Sciences Fund (PRHSX) is an actively managed, specialty mutual fund covering the health and biotech sectors. PRHSX is best suited for those investors who already have core equity positions and are looking for specialty exposure.

Managers of the fund use fundamental analysis to identify the best growth candidates from within the health care sector. As such, PRHSX provides exposure to a wide range of health care-related firms, including pharmaceuticals, biotech researchers, medical device companies, health insurers/benefits managers and hospital administrators/owners. Despite its narrow focus, expenses are on the low side. The fund is internally managed by T. Rowe Price.

PRHSX - Performance

Return Ranking - Trailing

Period PRHSX Return Category Return Low Category Return High Rank in Category (%)
YTD 11.5% -3.0% 17.2% 29.91%
1 Yr -5.5% -26.0% 6.3% 48.72%
3 Yr 6.4%* -15.2% 15.3% 33.94%
5 Yr 2.3%* -10.4% 12.8% 41.75%
10 Yr 11.7%* -2.7% 17.5% 27.96%

* Annualized


Return Ranking - Calendar

Period PRHSX Return Category Return Low Category Return High Rank in Category (%)
2018 -4.7% -25.3% 21.5% 33.33%
2017 19.1% -10.8% 43.9% 43.12%
2016 -14.2% -31.6% 6.9% 47.17%
2015 1.3% -20.4% 13.8% 23.30%
2014 17.6% -5.8% 31.5% 45.83%

Total Return Ranking - Trailing

Period PRHSX Return Category Return Low Category Return High Rank in Category (%)
YTD 11.5% -3.0% 17.2% 29.91%
1 Yr -5.5% -26.0% 6.3% 52.14%
3 Yr 6.4%* -15.2% 17.6% 47.71%
5 Yr 2.3%* -10.4% 18.3% 60.19%
10 Yr 11.7%* -2.7% 17.5% 51.61%

* Annualized


Total Return Ranking - Calendar

Period PRHSX Return Category Return Low Category Return High Rank in Category (%)
2018 -4.7% -25.3% 22.2% 41.44%
2017 19.1% -10.8% 45.8% 55.96%
2016 -14.2% -26.4% 8.7% 58.49%
2015 1.3% -16.6% 15.2% 62.14%
2014 17.6% -5.8% 36.7% 68.75%

NAV & Total Return History

PRHSX - Holdings

Concentration Analysis

PRHSX Category Low Category High PRHSX % Rank
Net Assets 11.9 B 2.52 M 42.7 B 3.15%
Number of Holdings 136 28 390 7.87%
Net Assets in Top 10 4.19 B 807 K 17.9 B 3.94%
Weighting of Top 10 37.80% 20.8% 76.5% 70.87%

Top 10 Holdings

  1. UnitedHealth Group Inc 6.15%

  2. Intuitive Surgical Inc 5.07%

  3. Becton, Dickinson and Co 4.78%

  4. Vertex Pharmaceuticals Inc 3.97%

  5. Thermo Fisher Scientific Inc 3.83%

  6. Stryker Corp 3.07%

  7. Pfizer Inc 3.05%

  8. Sage Therapeutics Inc 2.80%

  9. Anthem Inc 2.71%

  10. Danaher Corp 2.38%


Asset Allocation

Weighting Return Low Return High PRHSX % Rank
Stocks
99.61% 90.21% 103.54% 28.35%
Preferred Stocks
0.23% 0.00% 2.60% 18.11%
Cash
0.16% 0.00% 9.79% 83.46%
Other
0.00% -27.41% 3.81% 85.04%
Convertible Bonds
0.00% 0.00% 1.54% 92.91%
Bonds
0.00% 0.00% 20.60% 92.91%

Stock Sector Breakdown

Weighting Return Low Return High PRHSX % Rank
Healthcare
98.88% 56.60% 99.76% 9.45%
Basic Materials
0.58% 0.00% 1.66% 26.77%
Technology
0.15% 0.00% 22.28% 70.08%
Utilities
0.00% 0.00% 0.00% 92.91%
Real Estate
0.00% 0.00% 5.81% 94.49%
Industrials
0.00% 0.00% 3.11% 92.91%
Financial Services
0.00% 0.00% 5.48% 93.70%
Energy
0.00% 0.00% 0.31% 92.91%
Communication Services
0.00% 0.00% 2.11% 92.91%
Consumer Defense
0.00% 0.00% 33.15% 93.70%
Consumer Cyclical
0.00% 0.00% 5.27% 96.85%

Stock Geographic Breakdown

Weighting Return Low Return High PRHSX % Rank
US
90.18% 59.25% 99.76% 18.90%
Non US
9.43% 0.00% 40.06% 66.93%

PRHSX - Expenses

Operational Fees

PRHSX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.77% 0.10% 4.94% 87.18%
Management Fee 0.64% 0.09% 1.30% 48.03%
12b-1 Fee 0.00% 0.00% 1.00% 6.94%
Administrative Fee 0.15% 0.01% 0.40% 75.00%

Sales Fees

PRHSX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 2.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

PRHSX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 0.75% 2.00% N/A

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

PRHSX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 43.00% 0.00% 341.00% 58.47%

PRHSX - Distributions

Dividend Yield Analysis

PRHSX Category Low Category High PRHSX % Rank
Dividend Yield 0.00% 0.00% 4.41% 92.91%

Dividend Distribution Analysis

PRHSX Category Low Category High Category Mode
Dividend Distribution Frequency Annually Annually Semi-Annually Annually

Dividend Payout History


Net Income Ratio Analysis

PRHSX Category Low Category High PRHSX % Rank
Net Income Ratio 0.05% -2.24% 1.48% 37.61%

Capital Gain Distribution Analysis

PRHSX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually Annually

PRHSX - Managers

Ziad Bakri

Manager

Start Date

Tenure

Tenure Rank

Apr 01, 2016

3.5

3.5%

Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad brings a unique perspective to his new role, having been a medical doctor and an emergency medicine resident at the Royal London Hospital before beginning his investment career. Prior to joining T. Rowe Price, Ziad held biotechnology equity research and healthcare investment banking analyst positions in other investment firms


Tenure Analysis

Category Low

0.34

Category High

22.05

Category Average

9.62

Category Mode

19.43